Telesta Therapeutics Inc (BNHLF) stock price


In the news

Get notified when we upgrade Telesta Therapeutics Inc to a recommended stock

Free of charge we provide stock recommendations. Check our Best Stocks list.

Marketing by

Table History

Company Profile

Comparison table

Who was Telesta Therapeutics (symbol BNHLF)?

Telesta Therapeutics Inc. was engaged in researching and developing oncology and hematology therapies for its global markets. The company had two marketed products: HER2-targeted breast cancer therapy Herceptin (trastuzumab) and chronic myeloid leukemia (CML) treatment Ponatinib (Iclusig). Telstra's market capitalization as of August 13, 2017, was $52 million. Telesta was publicly traded with the symbol BNHLF; the company was based in Montreal, Quebec.
On November 7, 2016, it announced that it had delisted from the Toronto Stock Exchange and voluntarily delisted from NASDAQ.

Founded in 1998, the company had been under CEO Olivier Jankovski since November 8, 2016. In 2009, Telesta Therapeutics hit a milestone by being the first Canadian regulatory approval for an anti-cancer drug that is not approved anywhere else. However, as of October 4, 2018, the company no longer exists after being purchased by Kyowa Kirin Pharmaceuticals Company Limited.

What were the business strengths of Telesta Therapeutics?

Telesta was focused on developing and commercializing products to treat cancer pain individually tailored for each patient.
The company operates with three divisions:
The Consumer Division provides medications to patients living with cancer-related pain in Canada. It markets two leading brands in Canada, Relypsa, and Toviaz, each approved by Health Canada's regulatory body.
The Oncology Division specializes in developing and commercializing oncology drugs for hospitals, clinics, and cancer centers across North America.
The Manufacturing Division manufactures branded generic pharmaceuticals (Branded Generics).
Telesta Therapeutics aimed to develop treatments for human diseases through stem cells and other regenerative technologies. The company focused on developing treatments for neurodegenerative diseases by using stem cell research combined with its proprietary technology called mesenchymal progenitor cells (MPCs).
The company went public in November 2000 with the symbol BNHLF but was delisted following bankruptcy proceedings in 2009.